子宫体转移性或复发性子宫内膜样腺癌通常无法治愈，治疗选择有限。一线治疗通常包括细胞毒性化疗，这会给许多患者带来显着的毒性。子宫内膜癌，特别是子宫内膜样癌，是一种激素敏感性疾病，虽然单药激素疗法已显示出临床益处，但对这些药物的耐药性通常导致化疗的使用。对于大多数复发性子宫内膜癌，在转移性环境中缺乏批准的内分泌治疗方案，这代表了未满足的临床需求。新出现的证据表明，激素疗法与其他靶向治疗（例如细胞周期蛋白依赖性激酶 (CDK)4/6 抑制剂）相结合，在特定患者群体中具有良好的耐受性和有效性。我们讨论了临床证据，表明 CDK4/6 抑制剂和激素疗法的组合有可能成为低级别晚期或复发性子宫内膜癌患者一线治疗选择的重要补充。© IGCS 和 ESGO 2023。 CC BY-NC 允许重复使用。不得商业再利用。英国医学杂志出版。

Metastatic or recurrent endometrioid adenocarcinoma of the uterine corpus is often incurable with limited treatment options. First-line treatment often includes cytotoxic chemotherapy, which incurs significant toxicities for many patients. Endometrial cancer, specifically endometrioid cancer, is a hormone-sensitive disease and, while single-agent hormonal therapies have demonstrated clinical benefit, resistance to these agents often leads to the use of chemotherapy. There is a lack of approved endocrine treatment options in the metastatic setting for most recurrent endometrial cancers, representing an unmet clinical need. Emerging evidence suggests that hormonal therapy in combination with other targeted treatments, such as cyclin dependent kinase (CDK)4/6 inhibitors, is well tolerated and effective in select patient populations. We discuss the clinical evidence suggesting that the combination of CDK4/6 inhibitors and hormonal therapy has the potential to represent an important addition to the first-line treatment options for patients with low-grade advanced or recurrent endometrial cancer.© IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.